International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 21s, 2025
https://theaspd.com/index.php

Formulation And Characterization Of Nanofibers Incorporating Pravastatin For Potential Anti-Inflammatory Activity.

Swati R. Devkar[1], Manoj S. Tare[2], Rajesh B. Patil[3] , A.M.Avachat[4]
[1,2,3,4]Research Scholar, Savitribai Phule Pune University, Sinhgad College of Pharmacy, Vadgaon bk, Pune, Maharashtra, India-411041, [2]Professor, Shri Chhatrapati Sambhaji Shikshan Sanstha's Sitabai Thite College of Pharmacy, Shirur, Pune, Maharashtra, India-412210, [3]Principal, Sinhgad College of Pharmacy, Vadgaon bk Pune, Maharashtra, India-411041, Sinhgad College of Pharmacy, Vadgaon bk Pune, Maharashtra, India-411041

Abstract:
The current study investigates the formulation and characterisation of nanofibers formulation (POAF2) containing Pravastatin, Aloe vera juice, and onion oil for prospective anti-inflammatory applications. The organoleptic properties, solubility, UV, FTIR, and DSC analyses confirmed the compatibility of the drug and excipients, with no significant interactions observed. Phytochemical analysis identified bioactive substances in Aloe vera and onion oil, demonstrating their medicinal potential. Optimized nanofibre formulations demonstrated higher drug content (96.09%), entrapment efficiency was 94.84%, and extended drug release. Stability experiments conducted over a three-month period demonstrated no fluctuations in the drug's characteristics. The in vivo anti-inflammatory trial revealed a notable improvement with nanofibre therapy (40.60%) within 3 hr relative to the control group. Histopathological assessment revealed normal skin architecture with slight epithelial alterations in treated samples, further substantiating the promising therapeutic potential of these nanofibre compositions for anti-inflammation.
Keywords: *Nanofibers, Pravastatin, Aloe Vera Juice, Onion Oil, Histopathology, anti-inflammatory activity.*

1. INTRODUCTION:

Modern drugs is progressively shifting towards the more accurate and targeted administration of active pharmaceutical ingredients (APIs) at the designated site of action, with nanotechnology being a primary area of research to accomplish this objective. Nanotechnology involves the scientific, engineering, and technological disciplines focused on functioning systems at the nanoscale. These systems include specific attributes, including biological, physical, chemical, electronic, and optical characteristics that are very relevant in the fields of medical, pharmaceutical, materials, and engineering sciences.[(1, 2)] Nanotechnology was described to comprise particles or structures that fall within the size range of 1–100 nm in diameter.[(3)] From a pharmacological perspective, the term "nano" refers to particles or structures with a dimension of less than 1000 nm.[(4, 5)] The precise distribution of therapeutic agents to the site of action has long been a significant difficulty in the treatment of numerous illnesses. Numerous traditional delivery techniques exhibit restricted efficacy, insufficient selectivity, limited residence time, and inadequate bio distribution.[(6, 7)] where atoms and molecules display distinctive characteristics. The name "nano" originates from the Greek word for "dwarf," and nanoscience encompasses several disciplines, including physics, biology, chemistry, and engineering. It concentrates on events at the atomic and molecular scales, with a nanometer defined as one billionth of a meter. Nano science investigates structures at the Nano scale, whereas nanotechnology utilizes this understanding to develop functional devices. Nanotechnology use nanoscience to modify, monitor, and regulate matter at the nanoscale, allowing novel applications in domains such as health, electronics ,and materials science.[(8-10)] Nanofibers, initially fabricated by electrospinning over a century ago, are fibers with diameters under 100 nm, often derived from polymers using a technique utilizing strong electrostatic forces. These nanostructures possess distinctive characteristics, including elevated surface area, tensile strength, and little thermal expansion, rendering them advantageous for applications in healthcare (e.g., tissue engineering, wound care, and medication delivery), energy storage, and environmental remediation. Nanofibers can be produced from either natural or synthetic polymers, each presenting unique benefits. Nanofiber composites, which integrate many materials, improve attributes such as mechanical strength and cellular compatibility, rendering them especially advantageous in biological applications like nerve tissue engineering. These materials exhibit considerable potential for many industrial, medicinal, and advanced technological applications.[(11-13)]Nanofiber composites have much greater surface areas than traditional composites, augmenting their

strength without reducing volume fraction. Their extensive surface area mitigates suboptimal adhesion at the fiber-matrix contact. These composites can undergo surface treatment to enhance functional features, including optimized drug release kinetics. Coaxial electrospinning of PCL nanofibers with bioactive compounds such as FITC-BSA and PEG enhances protein loading and sustainability. Nanofiber composites demonstrate adjustable characteristics like as biodegradability, electrical conductivity, magnetic properties, and thermal conductivity, which may be customized for particular purposes. The interactions at the interface between nanofibers and matrix materials significantly affect the characteristics of composites, including bonding strength and dislocation density. (14-16)

2. MATERIALS AND METHODS

i. MATERIALS:

The chemicals used in the formulation include Pravastatin, HPMC K 4M, HPMC K 15M, PVP, Aloe vera juice, Onion oil, and Tamarind gum, all supplied by Cosmo Chem Pvt. Ltd. Ethanol was supplied by Merck.

ii. METHODS: (17-21)

A. Continuous hot Soxhlet extraction

The extraction of Aloe vera, onion, and other plant materials was performed using a Soxhlet extractor with solvents like methanol, ethanol, and chloroform. The materials were first dried in the shade, ground into coarse powder, and sieved to remove fine particles. The extraction was carried out until all desired components were extracted, with completion verified through TLC analysis, where the absence of colored spots indicated full extraction. After each extraction, solvents were distilled off, and the concentrated extracts were air-dried and stored in airtight containers. The process was repeated with different solvents (ethanol and chloroform) to ensure complete extraction.

B. Preliminary phytochemical investigations

I. Physicochemical evaluation

The physico-chemical characterization of selected plant materials would be carried out.

a. Determination of foreign organic matter

Principal:

The determination of foreign organic matter in herbal drugs involves examining 5 grams of dried material under magnification to isolate contaminants like insects, mold, and sand. The proportion of foreign matter is calculated based on the weight of the drug.

b. Determination of moisture content

The glass stopper and measuring bottle were weighed, and 2 grams of the sample were dried in an oven. After cooling in a desiccator, the weight loss was calculated as a percentage of the initial weight.

c. Ash value

Ash content in crude drugs determines their consistency and purity, including both physiological and non-physiological components. Total ash, acid-insoluble ash, and water-soluble ash are measured to assess the quality and purity of the plant material.

d. Determination of Total ash

2gm of aerated crude drug was correctly measured in a tared silica dish and incinerated at not more than 450 livres, before carbon-free, cooled and weight free was taken. The ash percentage was measured using the air-dried medication.

e. Determination of Water- soluble ash

Ash was collected and boiled with 25 ml of water for 5 minutes, then washed in hot water and ignited at 350°C for 15 minutes on an ash-free filter paper. The insoluble content was purified and collected, and the difference in weight between the insoluble substance and the ash determined the water-soluble ash percentage. This value was measured for the air-dried medication.

f. Determination of Acid -insoluble ash

According to the mentioned process, the ash was collected, boiled 5 minutes in 25 mL hydrochloric acid, washed in warm water and ignited cooled in a desiccator, and weighted in solutions on ash less filtering paper. The acid-insoluble ash proportion with the air-dried medication was measured.

g. Extractive values

Different extractive values like alcohol soluble extractive, water soluble extractive values were performed by standard method

h. Determination of water-soluble extractive value

Five grams of air-dried powdered drug were macerated with 100 ml of chloroform for 24 hours, with shaking during the first 6 hours. The water-soluble extractive value percentage was determined by evaporating and drying 25 ml of the filtered extract.

i. Determination of Alcohol-soluble extractive value

Five grams of coarsely powdered air-dried medicinal substance were macerated with 100 ml of ethanol for 24 hours, with shaking during the first 6 hours. The ethanol-soluble extractive value, based on air-dried drugs, was determined by evaporating 25 ml of the filtrate, drying it at 105°C, and weighing it.

II. Preliminary phytochemical investigations

Phytochemical tests for various compounds include Molisch's test for carbohydrates, Benedict's and Fehling's tests for reducing sugars, and Biuret's test for proteins. Additional tests for steroids, terpenoids, glycosides, saponins, alkaloids, tannins, phenolic compounds, and flavonoids are conducted using specific reagents and methods to identify the presence of each compound in plant extracts.

3. FORMULATION DEVELOPMENT

i. Preparation of solutions:

Prepare a PVP solution by dissolving 10 mg of PVP in 10 ml of ethanol. Then, create four solutions by adding specific amounts of Pravastatin, Onion oil, Aloe vera juice, and a combination of all three drugs with HPMC K4M, HPMC K15M, and Tamarind gum to the ethanolic PVP solution.

ii. Formulation Table

A. Pravastatin

Table 01: Formulation table of Pravastatin Nanofiber

Ingredients	PF1	PF2	PF3	PF4
Pravastatin	100	100	100	100
HPMC K4M(mg)	60	65	70	75
HPMC K15M(mg)	75	70	65	60
Tamarind gum(mg)	100	100	100	100
Ethanolic PVP	10 ml	10 ml	10 ml	10 ml

B. Onion oil

Table 02: Formulation table of Onion Nanofiber

Ingredients	OF1	OF2	OF3	OF4
Onion oil	3.6 ml	3.6 ml	3.6 ml	3.6 ml
HPMC K4M(mg)	60	65	70	75
HPMC K15M(mg)	75	70	65	60
Tamarind gum(mg)	100	100	100	100
Ethanolic PVP	10 ml	10 ml	10 ml	10 ml

C. Aloe vera Juice

Table 03: Formulation table of Aloevera Nanofiber

Ingredients	AF1	AF2	AF3	AF4
Drug	1 ml	1 ml	1 ml	1 ml
HPMC K4M(mg)	60	65	70	75
HPMC K15M(mg)	75	70	65	60
Tamarind gum(mg)	100	100	100	100
Ethanolic PVP	10 ml	10 ml	10 ml	10 ml

D. Pravastatin+ Onion oil+ Aloevera Juice

Table 04 : Formulation table of Pravastatin+ Onion oil+ Aloevera Juice Nanofibre

Ingredients	POAF1	POAPF2	POAPF3	POAPF4
Pravastatin+ Onion oil+ Aloevera Juice	104.6	104.6	104.6	104.6
HPMC K4M(mg)	60	65	70	75
HPMC K15M(mg)	75	70	65	60
Tamarind gum(mg)	100	100	100	100
Ethanolic PVP	10 ml	10 ml	10 ml	10 ml

iii.Preparation of nanofibers

The electrospinning process was carried out using a Fluidnatek LE-50 benchtopline with a variable high-voltage 0–35 kV power supply. The system was equipped with a motorized injector able to scan towards a metallic collector (20 × 20 cm2) that allows to obtain an homogeneous electrospun deposition. The corresponding solution (drug sample) was first placed into a 3 mL syringe, connected by polytetrafluoroethylene (PTFE) tubes to a stainless-steel needle of 0.7 mm of diameter. The needle tip was connected to the positive terminal of the power supply, while the metal collector was connected to the negative one. A piece of aluminum foil was placed on the collector and the solution was electrospun for about 5–10 min under a steady flow rate in the range 0.06–0.2 mL/h, depending on the sample, using the motorized injector. The distance between the needle tip and the collector was 15 cm (based on preliminary tests), and the voltage was varied for each sample depending on its properties. The process was conducted at 25 ◦C and at 40% relative humidity (RH). All the solutions prepared for electrospinning were fixed to present a 10 wt% composition of polymer, either natural, synthetic or in combination of both of them according to the study carried out.

4. EVALUATION PARAMETERS: [22-23]

I. PREFORMULATION STUDY:

A preformulation research was carried out to ensure that the medication and polymer were in a stable and pure state before being formulated into a dosage form also a for determinations of characteristics which may play important role in dosage form development.

Characterization of drug sample:

a) Organoleptic properties:

The appearance and pH of the drug were visually observed, and a digital pH meter was used to determine its pH level. For the color evaluation, a small amount of the drug was placed in butter paper and examined under a well-illuminated area. To assess the odor, only a very small quantity of the drug was used in order to avoid overwhelming the senses.

b) Melting point determination:

The drug's melting point was determined using the capillary method with a Thiele tube, where a capillary tube filled with drug powder was heated in liquid paraffin. The melting temperature was recorded by taking triplicate readings with a thermometer.

The λmax determination:

A. Pravastatin

1. Preparation of stock solution

A quantity of drug (10 mg) was dissolved in 20 ml of ethanol contained in 100 ml volumetric flask and was made up to mark with the same solvent to produce a 100 µg/ml solution.

2. Determination of wavelength of maximum absorption

1 ml was withdrawn from the stock solution into a 10 ml volumetric flask and made up to mark with ethanol to produce 10 µg/ml solution. This was then scanned in the spectrophotometer through range wavelengths (200 – 400 nm) so as to obtain the wavelength of maximum absorption.

The wavelength of maximum absorption is found to be 360nm.

3. Preparation of calibration curve

From the stock solution of various concentrations (10-50 µg/mL) prepared by pipetting appropriate volumes (0.1, 0.2, 0.3, 0.4, 0.5 mL) of standard solution into 10 ml volumetric flasks and diluting to volume with ethanol.

4.Fourier-transform infrared spectroscopy analysis

Fourier Transform Infrared (FT-IR) spectroscopy records the IR spectrum of a drug sample, which is compared to reference spectra to identify chemical functional groups. The technique uses an interferometer to capture the interferogram, which is then transformed into a conventional spectrum to aid in qualitative and quantitative analysis.

5.Compatibility study

Compatibility studies of APIs and excipients are conducted during preformulation to assess potential interactions that may affect the stability and efficacy of the final product. The API and excipients are mixed, stored at 37°C for 14 days, and analyzed using FTIR spectroscopy to detect any changes or interactions.

6. Differential Scanning Calorimetry

Differential Scanning Calorimetry (DSC) measures heat differences between a sample and reference to study physico-chemical interactions in formulation components. Using a DSC instrument, samples were analyzed under a dry nitrogen purge, heated and cooled at a constant rate to observe endothermic or exothermic effects.

7. Nuclear Magnetic Resonance Spectroscopy (NMR)

Nuclear Magnetic Resonance (NMR) spectroscopy is used to determine the structure of organic compounds by analyzing the magnetic properties of nuclei. It provides detailed information on chemical bonds, molecular dynamics, and conformation-activity relationships, with one-dimensional and two-dimensional techniques for studying simple and complex molecules.

B. Preformulation study of Aloevera

The organoleptic properties of Aloe vera, including appearance, pH, color, and odor, were assessed visually and with a pH meter. The melting point was determined using the capillary method with a Thiele tube, and the process was repeated thrice for accuracy. For λmax determination, a 100 µg/ml stock solution of Aloe vera was prepared, and its maximum absorption wavelength was found to be 478 nm. A calibration curve was prepared using various concentrations of the stock solution. Additionally, Fourier Transform Infrared (FT-IR) spectroscopy was used to record the IR spectrum of Aloe vera, identifying functional groups and providing a molecular fingerprint for qualitative and quantitative analysis

C. Preformulation study of Onion

A preformulation study was conducted to ensure the stability and purity of Onion before dosage form development. The organoleptic properties, including appearance, pH, color, and odor, were assessed visually and with a pH meter. The melting point was determined using the capillary method with a Thiele's tube, repeated for accuracy. For λmax determination, a 100 µg/ml stock solution of Onion was prepared, and its maximum absorption wavelength was found to be 410 nm. A calibration curve was also generated using various concentrations. Additionally, Fourier Transform Infrared (FT-IR) spectroscopy was used to record the IR spectrum of Onion, identifying functional groups and providing qualitative and quantitative information on the sample's composition.

5. POST FORMULATION [25-26]

Characterizations of Nanofibers

The preformulation and characterization of nanofibers involve several important analyses to assess drug content, loading, release, and stability. Drug content is determined by extracting the drug from nanofibers using a suitable solvent and quantifying it with UV-Vis spectroscopy. Drug loading is calculated based on the ratio of drug weight to nanofiber weight after electrospinning. Scanning electron microscopy (SEM) examines the nanofiber's surface morphology, while drug entrapment efficiency is measured using ultracentrifugation and UV-Vis spectroscopy. Production yield is determined by comparing the nanofiber

mass to the total polymer and drug weight. In-vitro drug release studies use phosphate buffer saline (PBS) at 37°C, with samples analyzed by UV-Vis spectroscopy. Thermal stability is analyzed using TGA, and high-resolution images are obtained using Transmission Electron Microscopy (TEM). Nanofiber stability is tested over three months at 4°C by assessing particle size, zeta potential, entrapment efficiency, and physical appearance.

6. INVIVO ACTIVITY: [27]

I. Anti-Inflammatory activity.

Animal Model: In vivo Anti-Inflammatory activity.

Test Item: - Nanofiber film containing Pravastatin

Dose: -

- F1 = normal distilled water
- F2 = Nanofiber film containing Pravastatin
- **Experimental design (Grouping Nanofiber film containing Pravastatin)**

Group I	Rats were subjected to F1 to normal distilled water for Topically administrate.	No. of Animals used 06
Group II	Rats were subjected to after carrageenan injection of the hind paw and did not undergo any treatment.	06
Group III	Rats were subjected to F2 to Nanofiber film containing Pravastatin for Topically administrate.	06

Experimental condition: -

Albino rats (Wistar strain) of either sex weighing about 250-300 g were used in this study. The animals were kept in the standard metabolic cages in groups of six per cage, with free access to standard diet and water ad libitum. They are maintained at room temperature under suitable nutritional and environmental conditions throughout the experiment. The Institutional Animal Ethics Committee reviewed the entire animal protocol prior to conducting the experiments.

Procedure:

Wistar rats were divided into 3 groups, with 6 rats in each. The second group was inflamed by carrageenan injection and did not undergo any treatment. The inflammation of the second group, used as reference, and that of the third group was treated by F2 to Nanofiber film containing Pravastatin for topically administrate, 1/2 hour before the carrageenan injection. The doses Test item (F1, F2,) chosen during treatments were proportional in the size of the edema and covered the whole swelling. Test item Nanofiber film containing Pravastatin for topically administrate. In all treated groups, the size of the edema was measured before and after the inflammatory injection using a digital caliper. Edema was expressed as the relative increase in paw volume induced by the inflammation injection (i.e., the edema was proportional to the volume difference between 0 hours and the other times, 30 min, 60, 120, and 180 min, after carrageenan injection).

Percentile edema inhibition was calculated according to following

Formula: - Percentile inhibition = [1-(VT/V0)] X 100

VT represents the edema volume in the drug treated group.

V0 represents the edema volume in the Carr group.

Histopathology of the skin tissue:

On the 21st day, the animals were sacrificed after being anesthetized, inflamed skin tissue samples were collected after sacrificing the rats for histopathological examination purposes. These tissue samples were fixed at 10% neutral buffered formalin solution, embedded in paraffin wax, cut into 5 μM-thick sections and stained with hematoxylin-eosin and Masson's trichrome stain for examination by light microscopy.

7. RESULT & DISCUSSION

1. PREFORMULATION STUDY:

a) Organoleptic properties:

The organoleptic properties of the substances were as follows: Pravastatin is a white to yellowish crystalline powder with no noticeable odor. Aloe vera juice, derived from succulent leaves arranged in a rosette, has a grey to green color and a mild, pungent odor. Onion oil appears as a brownish yellow oily globule with an obnoxious sulfide odor.

b) Melting point determination:

The melting points of the samples were as follows: Pravastatin had a melting point of 172.12°C, Aloe vera juice melted at 36.10°C, and Onion oil had a melting point of 40.13°C.

c) Solubility:

The solubility of Pravastatin in various mediums was as follows: Methanol (0.368 µg/ml), Ethanol (0.2415 µg/ml), DMSO (0.458 µg/ml), and Phosphate buffer pH 6.8 (0.125 µg/ml). For Onion oil, the solubility in Methanol was 0.547 µg/ml, Ethanol was 0.2915 µg/ml, DMSO was 0.258 µg/ml, and in Phosphate buffer pH 6.8, it was 0.09 µg/ml. The solubility of Aloe vera juice in various mediums was as follows: Methanol (0.347 µg/ml), Ethanol (0.2215 µg/ml), DMSO (0.358 µg/ml), and Phosphate buffer pH 6.8 (0.115 µg/ml).

d) UV Spectroscopy

Pravastatin:

UV Spectroscopy:

The λmax determination:

It is done by using UV-Spectrophotometer. The wavelength of maximum absorption is found to be 230



nm.

Fig no 1 : UV spectra of Pravastatin

Table 5: Absorbance of Pravastatin

Concentration(µgmL-1)	Absorbance(nm)
0.1	0.2587
0.2	0.5001
0.3	0.7241
0.4	0.9524
0.5	1.2017
0.6	1.4215



Fig no 3. Linearity Curve for Pravastatin

a) Fourier-transform infrared spectroscopy analysis



Fig no 4: FTIR Spectra of Pure Pravastatin

b) Compatibility study



Fig no 5: Compatibility study by FTIR spectra

c) Differential Scanning Calorimetry



Fig no 6: DSC Graph of Pure Pravastatin



Fig no 7: Compatibility study by DSC Graph for mixture

B- Aloevera Juice

a) UV Spectroscopy:

The λmax determination:

It is done by using UV-Spectrophotometer. The wavelength of maximum absorption is found to be 478 nm.



Fig no 8: UV spectra of Aloevera

Table 6: Absorbance of Aloevera

Concentration(µgmL-1)	Absorbance(nm)
0.1	0.2571
0.2	0.4501
0.3	0.6205
0.4	0.9504
0.5	1.1087
0.6	1.2279



Fig no 9. Linearity Curve for Aloevera

b) Fourier-transform infrared spectroscopy analysis



Fig no 10: FTIR Spectra of Aloevera

C. Onion oil

a) UV Spectroscopy:

The λmax determination:

It is done by using UV-Spectrophotometer. The wavelength of maximum absorption is found to be 410 nm.



Fig no 11: UV of Onion Oil



Fig no 12. Linearity Curve for Aloevera

Table 7: Absorbance of Onion

Concentration(µgmL-1)	Absorbance(nm)
0.1	0.2571
0.2	0.4581
0.3	0.7205
0.4	0.9504
0.5	1.2087
0.6	1.3279

b) Fourier-transform infrared spectroscopy analysis



Fig no 13: FTIR Spectra of onion

Table No. 8: Spectrum interpretation of Aloevera

Functional group	**Wave number (cm^{1})**
Hydroxyl group OH	3062.0
C–H asymmetric stretching in CH_2	2929.7
C=O Stretching	2858.3
C=C	1604.7
CO group	1056.5

D. Aloevera Juice and onion oil

1. Determination of foreign organic matter:

Foreign organic matter in Aloevera Juice and onion oil was found to be 0.42% w/w and 0.48 w/w when observed under 6X lens.

2. Determination of moisture content:

The observation of the loss on drying of Aloe vera juice showed the following moisture loss percentages: at 0 minutes, 0.00%; at 30 minutes, 0.320%; at 60 minutes, 0.210%; at 90 minutes, 0.170%; and at 120 minutes, 0.183%. Another trial recorded the following values: 0.00% at 0 minutes, 0.315% at 30 minutes, 0.209% at 60 minutes, 0.165% at 90 minutes, and 0.180% at 120 minutes. The values are expressed as mean ± SEM, with n=3.

3. Determination of Ash value:

Ash value is useful in determining authenticity and purity of sample and also these values are important qualitative standards.

The ash value of Aloe vera juice was evaluated in two trials. In the first trial, the total ash value was 2.7%, acid-insoluble ash was 0.32%, and water-soluble ash was 0.9%. In the second trial, the total ash value was

2.4%, acid-insoluble ash was 0.31%, and water-soluble ash was 0.15%. The values are presented as mean ± SEM, with n=3.

4. Determination of Extractive values: -

Ethanol-soluble extractive value was found to be greater than other extractive value; it indicates that compounds present in the leaves are soluble in alcohol in high amount. This might guide us for the isolation of maximum active components form plant.

The extractive values of Aloe vera juice were determined in two trials. In the first trial, the ethanol-soluble extractive value was 15%, and the water-soluble extractive value was 3.7%. In the second trial, the ethanol-soluble extractive value was 17%, and the water-soluble extractive value remained at 3.7%. The values are expressed as mean ± SEM, with n=3.

5.Preliminary Phytochemical Screening of Aloevera Juice

Aloevera were tested for the presence of active principles such as Terpenoid, Steroids, Glycosides, Saponins, Alkaloids, Flavonoids, Tannins, Proteins, Free Amino Acids, Carbohydrate and Vitamin C. Qualitative chemical test used to identify drug quality and purity. The identification, isolation and purification of active chemical constituents are depending chemical methods of evaluation. The preliminary phytochemical screening of Aloe vera juice extracts using methanol, ethanol, and chloroform revealed the presence of various phytoconstituents. Carbohydrates were detected by the Fehling test in all solvents, while other tests like Molish and Benedict were positive in ethanol. Proteins were present in methanol, ethanol, and chloroform extracts, and steroids were found in methanol and ethanol. Terpenoids were observed in methanol and ethanol, while glycosides were negative in all extracts except for the Killer-Killani test in ethanol. Saponins were detected in methanol, and flavonoids were present in ethanol. Alkaloids were found in both ethanol and chloroform, and tannins and phenolic compounds were present in all extracts

6. Preliminary Phytochemical Screening of Onion

Onion Extracts were tested for the presence of active principles such as Terpenoid, Steroids, Glycosides, Saponins, Alkaloids, Flavonoids, Tannins, Proteins, Free Amino Acids, Carbohydrate and Vitamin C. Qualitative chemical test used to identify drug quality and purity. The identification, isolation and purification of active chemical constituents are depending chemical methods of evaluation. The preliminary phytochemical screening of Onion extracts (methanol, ethanol, and chloroform) revealed the presence of various phytoconstituents. Carbohydrates were detected by the Fehling test in all solvents, while the Molish and Benedict tests showed positive results in ethanol. Proteins were present in methanol, ethanol, and chloroform, with steroids detected in methanol and ethanol. Terpenoids were observed in both methanol and ethanol, while glycosides were absent, except in ethanol for the Killer-Killani test. Saponins were found in methanol, and flavonoids were present in ethanol. Alkaloids were detected in ethanol and chloroform, and tannins and phenolic compounds were present in all extracts.

The all extracts were screened for the presence of various constituents. The result of this preliminary phytochemical examination is shown in Table.

The ethanol extract showed presence of significant metabolites like alkaloids, glycoside and flavonoids. So the ethanol extract will utilize for further plan of research work.

7. Characterizations of Nanofibers

After formulating the nanofiber with specified parameters, the batch is optimised i.e. NF2 is considered as optimised batch.

I.Drug Content:

A. Pravastatin Nanofibers

The drug content percentage in the formulation batches was as follows: PF1 had 91.42%, PF2 showed 97.37%, PF3 contained 92.34%, and PF4 had 90.14%.

B. Onion oil

The drug content percentages for the formulation batches were as follows: OF1 had a drug content of 92.04%, OF2 contained 96.28%, OF3 had 93.09%, and OF4 showed a drug content of 91.24%.

C. Aloevera Juice

The drug content percentages for the formulation batches were as follows: AF1 had a drug content of 90.19%, AF2 contained 98.91%, AF3 had 90.02%, and AF4 showed a drug content of 94.19%.

D. Pravastatin+ Onion oil+ Aloevera Juice

The drug content percentages for the formulation batches were as follows: POAF1 had a drug content of 90.37%, POAF2 contained 96.09%, POAF3 had 88.19%, and POAF4 showed a drug content of 94.29%.

II. Entrapment Efficiency (%)

A. Pravastatin Nanofibers

The entrapment efficiency percentages for the formulation batches were as follows: PF1 had an entrapment efficiency of 86.46%, PF2 showed 91.09%, PF3 had 85.12%, and PF4 exhibited an entrapment efficiency of 85.04%.

B. Onion oil

The entrapment efficiency percentages for the formulation batches were as follows: OF1 had an entrapment efficiency of 89.04%, OF2 showed 91.17%, OF3 had 87.01%, and OF4 exhibited an entrapment efficiency of 86.27%.

C. Aloevera Juice

The entrapment efficiency percentages for the formulation batches were as follows: AF1 had an entrapment efficiency of 89.12%, AF2 showed 91.81%, AF3 had 87.82%, and AF4 exhibited an entrapment efficiency of 86.72%.

D. Pravastatin+ Onion oil+ Aloevera Juice

The entrapment efficiency of the Pravastatin, Onion Oil, and Aloe Vera Juice nanofiber formulations (POAF1-POAF4) ranged from 86.61% (POAF3) to 94.84% (POAF2), with POAF1 and POAF4 showing efficiencies of 88.94% and 89.72%, respectively.

III. Drug Loading (%)

A. Pravastatin Nanofibers

The drug loading percentages for the formulation batches were as follows: PF1 had a drug loading of 6.06%, PF2 contained 8.21%, PF3 had 5.09%, and PF4 exhibited a drug loading of 5.19%.

B. Onion oil

The drug loading percentages for the formulation batches were as follows: OF1 had a drug loading of 4.28%, OF2 contained 8.14%, OF3 had 7.51%, and OF4 exhibited a drug loading of 6.19%.

C. Aloevera Juice

The drug loading percentages for the formulation batches were as follows: AF1 had a drug loading of 4.12%, AF2 contained 6.11%, AF3 had 5.08%, and AF4 exhibited a drug loading of 4.29%.

D. Pravastatin+ Onion oil+ Aloevera Juice

The drug loading percentages for the formulation batches were as follows: POAF1 had a drug loading of 4.90%, POAF2 contained 7.27%, POAF3 had 6.67%, and POAF4 exhibited a drug loading of 5.07%.

IV. Diffusion Study:

A. Pravastatin Nanofibers

Table 9: Drug Release of Pravastatin Fibre (PF1-PF4)

Time (hrs)	PF1	PF2	PF3	PF4
0	0	0	0	0
1	10.24	9.47	12.14	9.87
2	25.37	18.46	21.85	19.48
3	34.31	28.45	30.19	29.16
4	49.78	39.45	41.85	38.67
5	54.32	50.04	51.75	51.48
6	69.47	65.48	66.94	69.82
7	80.45	85.45	81.25	72.48
8	89.28	**94.37**	90.14	88.29



Fig no 14: Drug Release of Pravastatin Fibre (PF1-PF4)

.B. Onion oil

Table 10: Drug Release of Onion oil Fibre (OF1-OF4)

Time (hrs)	OF1	OF2	OF3	OF4
0	0	0	0	0
1	9.04	9.47	10.29	9.71
2	15.17	18.46	19.13	18.59
3	33.29	28.45	29.07	21.29
4	44.10	39.45	41.42	39.46
5	54.09	50.04	53.43	51.48
6	71.73	65.48	67.37	69.02
7	80.64	85.45	80.76	77.41
8	88.17	**95.37**	89.37	89.09



Fig no 15: Drug Release of Onion oil Fibre (OF1-OF4)

C. Aloevera Juice

Table 11: Drug Release of Onion oil Fibre (AF1-AF4)

Time (hrs)	AF1	AF2	AF3	AF4
0	0	0	0	0
1	10.21	7.28	11.04	10.09
2	15.64	17.09	19.19	19.59
3	30.91	25.94	21.09	27.29
4	41.29	37.51	32.09	38.07
5	55.73	59.73	49.17	49.39
6	68.82	65.17	69.29	61.82
7	80.64	87.04	75.58	81.27
8	89.17	96.37	85.91	91.09



Fig no 16: Drug Release of Onion oil Fibre (AF1-AF4)

D. Pravastatin+ Onion oil+ Aloevera Juice

Table 12 : Drug Release of Onion oil Fibre (POAF1-POAF4)

Time (hrs)	POAF1	POAF2	POAF3	POAF4
0	0	0	0	0
1	8.26	7.23	13.04	9.09
2	19.21	15.73	21.46	17.47
3	35.64	29.10	31.76	21.64
4	45.09	39.43	38.34	35.41
5	59.54	59.73	43.86	47.27
6	65.16	67.37	61.07	69.31
7	79.34	82.79	71.07	79.91
8	87.39	94.04	81.27	89.07



Fig no 17: Drug Release of Onion oil Fibre (POAF1-POAF4)

V. Scanning electron microscopy



Fig no18: The Nanofibers view under X 5.00 K magnification





Fig 19: The Nanofibers under X 10.00 K magnification
Fig no 20: The Nanofibers view under X 50.00 K magnification
Fig no 21: The Nanofibers view under X 100.00 K magnification



VI. Stability Study:

1. **Optimized Batch of Pravastatin nanofibre (PF2)**

Table 13: Optimized Batch of Pravastatin nanofibre (PF2)

Stability parameter	Initial	1 month	2 month	3 month
Drug Content (%)	97.37	97.37	97.36	97.36
Entrapment efficiency (%)	91.02	91.02	91.02	91.00
Drug release (%)	94.37	94.37	94.37	94.36

2. Optimized Batch of Onion oil nanofibre (OF2)

Table 14: Optimized Batch of Onion oil nanofibre (OF2)

Stability parameter	Initial	1 month	2 month	3 month
Drug Content (%)	96.28	96.28	96.27	96.27
Entrapment efficiency (%)	91.17	91.17	91.17	91.16
Drug release (%)	95.37	95.37	95.36	95.36

3. Optimized Batch of Aloevera nanofibre (AF2)

Table 15: Optimized Batch of Aloevera nanofibre (AF2)

Stability parameter	Initial	1 month	2 month	3 month
Drug Content (%)	98.91	98.91	98.90	98.90
Entrapment efficiency (%)	91.81	91.81	91.81	91.80
Drug release (%)	96.37	96.37	96.36	96.36

4. Optimized Batch Pravastatin+ Onion oil+ Aloevera nanofibre (POAF2)

Table 16: Optimized Batch Pravastatin+ Onion oil+ Aloevera nanofibre (POAF2)

Stability parameter	Initial	1 month	2 month	3 month
Drug Content (%)	96.09	96.09	96.08	96.08
Entrapment efficiency (%)	94.84	94.84	94.84	94.83
Drug release (%)	94.04	94.04	94.03	94.03

VII. In vivo activity:

Anti-Inflammatory activity

Sr.no	Treatments Group	Mean Paw edema in different time intervals					% edema inhibition in different time intervals			
		0 min	30 min	60 min	120 min	180 min	30 min	60 min	120min	180 min
1	Group I	3.46 ± 0.17	3.57 ± 0.63	3.63 ± 0.76	3.61 ± 0.086	3.37 ± 0.16				
2	Group II	4.16 ± 0.025	8.09 ± 0.087	7.89± 0.032	7.76 ± 0.048	7.66 ± 0.085	-	-	-	-
3	Group III	5.01 ± 0.089	7.91 ± 0.087	7.44 ± 0.154	6.31 ± 0.056	4.55 ± 0.086	**2.224**	**5.70%**	**18.68%**	**40.60%**

HISTOPATHOLOGY REPORT:-:

Exhibited a normal structure and architecture. No pathological changes were observed. No inflammatory infiltration. No abnormality detected. **Normal S1 (10X)**	**Normal S1 (40X)**
100 µm	
Marked increase in synovial hyperplasia and inflammatory cell infiltration. Structural changes were observed. Severe abnormality were detected. **Control S1 (10X)**	**Control S1 (40X)**

Exhibited a normal structure and architecture. Mild hemorrhage were observed. No pathological changes were observed. No inflammatory infiltration. No abnormality detected. Nanofiber film containing Pravastatin **S1 (10X)**	Nanofiber film containing Pravastatin **S1 (40X)**

8. SUMMARY AND CONCLUSION:

The study assessed the organoleptic properties, solubility, UV, FTIR, DSC, and phytochemical components of Pravastatin, Aloe vera juice, and Onion oil. Pravastatin was white to yellowish, Aloe vera juice had a greenish hue with a mild odor, and Onion oil was brownish-yellow with a sulfide scent. Solubility testing showed Pravastatin was least soluble in phosphate buffer, while Onion oil was better soluble in methanol. UV and FTIR analyses confirmed no significant interactions between Pravastatin and excipients, ensuring compatibility for nanofiber formulation, which was further supported by DSC results. Phytochemical screening revealed bioactive compounds in Aloe vera and Onion oil, suggesting their therapeutic potential. The nanofiber formulations exhibited good drug content, entrapment efficiency, and sustained drug release. Stability studies showed minimal changes over three months, and the in vivo anti-inflammatory study demonstrated a significant improvement in % edema inhibition in different time intervals (40.60%) compared to the control group. Histopathology indicated mild epithelial changes in some treated samples, confirming the nanofibers' potential for effective anti-inflammation.

9. CONFLICT OF INTEREST

Nil

10. REFERENCE S

1. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine—challenge and perspectives. Angewandte Chemie International Edition. 2009 Jan 19;48(5):872-97.

2. Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, Fu T, Tan W. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine. 2012 Aug 1;7(8):1253-71.

3. Chauhan I, Verma M, Yasir M. Nanoethics and nanotechnology. Nanotechnology in medicine: Toxicity and safety. 2021 Dec 3:349-72.

4. Williams III RO, Vaughn JM. Nanoparticle engineering. Encyclopedia of pharmaceutical technology. 2007;4:2384-98.

5. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. American journal of respiratory and critical care medicine. 2005 Dec 15;172(12):1487-90.

6. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacological reports. 2012 Sep 1;64(5):1020-37.

7. Aminu NA, Toh SM. Applicability of nanoparticles-hydrogel composite in treating periodontal diseases and beyond. Asian J Pharm Clin Res. 2017;10(2):65-70.http://www.nanoscience.com/education/overview.html.

8. http://powersof10.com

9. Mansoori, G.; Fauzi Soelaiman, T. Nanotechnology—An Introduction for the Standards Community. J. ASTM Int. 2005, 2, 1–22.

10. Gnach, A.; Lipinski, T.; Bednarkiewicz, A.; Rybka, J.; Capobianco, J.A. Upconverting nanoparticles: Assessingthe toxicity. Chem. Soc. Rev. 2015, 44, 1561–1584

11. National Nanotechnology Initiative (NNI). Available online: www.nano.gov (accessed on 22 July 2019).).

12. Allho_, F. On the Autonomy and Justification of Nanoethics. Nanoethics 2007, 1, 185–210.

13. Sagadevan S, Periasamy M. A review on role of nanostructures in drug delivery system. Rev Advanced Mater Science, 36:112-117, 2014.)

14. Lucian A L, Rojas O J. Fiber nanotechnology: a new platform for green research and technological innovations. Cellulose, 14:539-542, 2014.)

15. Hung ZM, Zhangb YZ, Kotakic M, Ramakrishna S. A review on polymer nanofibers by electro spinning and their applications in nanocomposites. Composites Science and Technology, 63, 2003, 2223–2253.).

16. Poole Charles Jr and Frank J. Owens. Introduction to nanotechnology. John Wiley and Sons, NY, 470-479, 2003.)

17. Horacio A., Jose R., Flor H., German F., 1997. Cytotoxicity of low molecular weight fraction from Aloe vera (Aloe Barbedensis Miller) Gel. Toxicon Vol. 35, No. 9, 1423 – 1430

18. Ramchandra C.T., Shrinivasa Rao P., 2008. Processing of Aloe vera Gel. American Journal of Agriculture and Biological Science, Vol.3, No.2, 502 – 510.

19. Okamiura N., Norika Hine., Yukko Tateyama., Motoko Naakazawa., Toshihiro Fujioka., Kunihide Mihashi., Akira Yagi.,1997. Three Chromones of Aloe Vera leaves. Www.elvister.com. Phytochemistry, Vol. 45, No. 7, 1511 – 1513.

20. Reynolds T., Dweck A.C., 1996. Aloe vera leaf Gel: A review update. Journal of Enthropharmacology, 68, 3 – 37.

21. Yaawei Ni., Kenneth M., Ryszard Z., 2006. Pharmacological Composing Pectins having High Moleqular weight and Low Degree of methoxilation. United State Patent, No. 7,022,683.

22. .Kathi Kemper J., Chiou V., 1999. Aloe vera. The Longwood Herbal Task Fource., http:/www. mcp.edu/ herbal/ default.htm

23. Teresa P., Gazzola M., Mucigant C., Parolin C., Dalla Vecchia F., 2000. Aloeemodin is a New Type of Anticancer agent with selective activity against Nuroectodermal tumor. Cancer Research.60, 2800 – 2804.
24. Maenthaisong R., Chaiyakunapruk N., Niruntraporn S., 2007.The efficacy of aloe vera used for burn wound healing. Burn Vol. 23, 713 – 718.
25. Ayse C., Nuriye A., 2004. Effect of Aloe vera Gel and Pulp Extract on the Liver Type-2 Diabetic Rat models. Biol. Pharm. Bull., Vol. 27, No. 5, 694 – 698.
26. Christian Robe., Musch A., Peter Schirmacher S. Wolfgang K., Robert Hoffmann., 2005. Acute Hepatitis induced by an Aloe vera preparation. World J. Gastroenterology, Vol.55, 69 – 75.
27. Taiwo V.O., Olukunle O.A., Ozor I.C., Oyejobi A.T., 2005. Consumption of aqueous extract of raw Aloe vera leaves: Histopathological and Biochemical Studies in Rat and Tilapia. African Biomed. Sci., Vol. 8, 169 – 178.